ArticleInvestigative ophthalmology & visual science2025
Celastrol Activates SIRT1/PGC-1α/Nrf2 Axis to Inhibit Oxidative Damage for Subconjunctival Fibrosis Alleviation.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting CRBN With Thalidomide Suppresses Fibrosis After Glaucoma Drainage Surgery Through NF-κB Pathway Inhibition.Investigative ophthalmology & visual science · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Subconjunctival fibrosis can lead to symblepharon and recurrent pterygium, seriously threatening vision. Our previous research found that celastrol could inhibit subconjunctival fibrosis. The purpose of this study was to investigate the underlying mechanisms of celastrol-nanomicelles (Cel) in inhibiting subconjunctival fibrosis. Methods: We established rat subconjunctival injury model in vivo and TGF-β1-activated human pterygium fibroblasts systems in vitro to study fibrotic pathogenesis. RNA-seq analysis was used to identify the targets of Cel. Immunofluorescence and Western blot analyses were performed to determine whether Cel modulates the SIRT1/PGC-1α/Nrf2 axis, thereby alleviating oxidative damage and subconjunctival fibrosis in vitro. The critical involvement of the SIRT1/PGC-1α/Nrf2 axis was definitively established through pharmacological inhibition using EX527, a selective SIRT1 antagonist. Moreover, the effects of Cel on subconjunctival fibrosis in vivo were further explored through histopathological assessments, Masson's trichrome staining, and immunofluorescence. Results: In vivo evaluation with a rat subconjunctival injury model showed that Cel effectively attenuated oxidative damage and subconjunctival fibrosis. The RNA-seq analysis indicated that SIRT1 signal and oxidative stress regulation as candidate targets of Cel for subconjunctival fibrosis. The results of immunofluorescence and Western blot showed that Cel inhibited subconjunctival fibrosis by activating SIRT1/PGC-1α/Nrf2 axis and suppressing TGF-β1/Smad2/3 pathway, while the SIRT1 inhibitor eliminated the effects of Cel. Conclusions: This work demonstrated that Cel effectively alleviated subconjunctival fibrosis by inhibiting oxidative damage via activating SIRT1/PGC-1α/Nrf2 signaling pathway, providing a new potential mechanism to clarify Cel as a potential therapeutic drug to inhibit subconjunctival fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.